Advertisement

Topics

FDA Investigates 'Adverse Events' From Compounded Injectable Product

06:48 EST 9 Nov 2017 | Pharmaceutical Processing

Patients developed what is described as tissue erosion at the injection site following the administration of a product that was compounded by United Pharmacy, LLC.
Contributed Author: 
FDA MedWatch
Topics: 

Original Article: FDA Investigates 'Adverse Events' From Compounded Injectable Product

NEXT ARTICLE

More From BioPortfolio on "FDA Investigates 'Adverse Events' From Compounded Injectable Product"

Advertisement
Quick Search
Advertisement
Advertisement